Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis
Allergan · Diabetes Mellitus · Diabetes Mellitus Complications
Phase 2
Completed
393
2019-07
Evidence dashboardStudies since 2011Updated Jul 31, 2026
RelamorelinClinical Trials.
A source-linked view of every Relamorelin study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 13
- Recruiting
- 0
- Completed
- 7
- Terminated
- 6
- Results posted
- 6
- Average enrollment
- 193
- Countries
- 31
- Highest phase
- Phase 3
Largest indexed study
467 participants · NCT03420781 →Developer / research origin
Allergan
Evidence summary
Activity is not efficacy.
Relamorelin appears in 13 indexed studies: 0 recruiting, 7 completed and 6 with registry results posted. The highest registered development stage in this snapshot is Phase 3. These counts measure registry activity; they do not establish that Relamorelin is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
No studies in this snapshot.
NCT IDStudyPhase / statusEnrollmentUpdated
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
Motus Therapeutics, Inc. · Diabetes Mellitus · Diabetes Mellitus Complications
Phase 2
Completed
204
2016-09
Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa
Motus Therapeutics, Inc. · Anorexia Nervosa
Phase 2
Completed
20
2016-09
Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation
Motus Therapeutics, Inc. · Constipation
Phase 2
Completed
48
2016-09
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
Motus Therapeutics, Inc. · Diabetes Mellitus Type 1 and 2 · Diabetes Mellitus Complications
Phase 1
Completed
20
2016-09
Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation
Motus Therapeutics, Inc. · Chronic Constipation
Phase 1
Completed
18
2016-09
Showing 6 of 7 studies
NCT IDStudyPhase / statusEnrollmentUpdated
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
Allergan · Gastroparesis · Diabetes Mellitus
Phase 3
Terminated
467
2021-12
Diabetic Gastroparesis Study 05
Allergan · Gastroparesis
Phase 3
Terminated
202
2021-12
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
Allergan · Gastroparesis · Diabetes Mellitus
Phase 3
Terminated
450
2021-11
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
Allergan · Gastroparesis · Diabetes Mellitus
Phase 3
Terminated
311
2021-08
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
Allergan · Gastroparesis · Diabetes Mellitus
Phase 3
Terminated
336
2021-07
A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation
Motus Therapeutics, Inc. · Parkinson's Disease
Phase 2
Terminated
18
2016-09
Full study index
Search Relamorelin trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
13 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 40148033 ↗Camilleri M, Jencks KJ. Pharmacologic treatments for gastroparesis. Pharmacol Rev. 2025 Mar;77(2):100019. doi: 10.1016/j.pharmr.2024.100019. Epub 2024 Nov 23.Linked from NCT03285308PMID 32301137 ↗Camilleri M, Lembo A, McCallum R, Tourkodimitris S, Kemps L, Miller MB, Bertelsen K, Iacob A. Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data. Aliment Pharmacol Ther. 2020 Jun;51(11):1139-1148. doi: 10.1111/apt.15711. Epub 2020 Apr 17.Linked from NCT02357420PMID 28760384 ↗Camilleri M, McCallum RW, Tack J, Spence SC, Gottesdiener K, Fiedorek FT. Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. Gastroenterology. 2017 Nov;153(5):1240-1250.e2. doi: 10.1053/j.gastro.2017.07.035. Epub 2017 Jul 29.Linked from NCT02357420PMID 27055601 ↗Lembo A, Camilleri M, McCallum R, Sastre R, Breton C, Spence S, White J, Currie M, Gottesdiener K, Stoner E; RM-131-004 Trial Group. Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis. Gastroenterology. 2016 Jul;151(1):87-96.e6. doi: 10.1053/j.gastro.2016.03.038. Epub 2016 Apr 4.Linked from NCT01571297PMID 29325236 ↗Fazeli PK, Lawson EA, Faje AT, Eddy KT, Lee H, Fiedorek FT, Breggia A, Gaal IM, DeSanti R, Klibanski A. Treatment With a Ghrelin Agonist in Outpatient Women With Anorexia Nervosa: A Randomized Clinical Trial. J Clin Psychiatry. 2018 Jan/Feb;79(1):17m11585. doi: 10.4088/JCP.17m11585.Linked from NCT01642550PMID 26467700 ↗Acosta A, Camilleri M, Busciglio I, Boldingh A, Nelson AD, Burton D. Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial. Dig Dis Sci. 2016 Mar;61(3):852-60. doi: 10.1007/s10620-015-3876-5. Epub 2015 Oct 14.Linked from NCT01781104PMID 26001337 ↗Acosta A, Camilleri M, Kolar G, Iturrino J, Szarka LA, Boldingh A, Burton D, Ryks M, Rhoten D, Zinsmeister AR, Spence SC, Gottesdiener K, Bouras EP, Vazquez-Roque MI. Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial. Clin Gastroenterol Hepatol. 2015 Dec;13(13):2312-9.e1. doi: 10.1016/j.cgh.2015.04.184. Epub 2015 May 19.Linked from NCT01781104PMID 23639598 ↗Shin A, Camilleri M, Busciglio I, Burton D, Smith SA, Vella A, Ryks M, Rhoten D, Zinsmeister AR. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol. 2013 Nov;11(11):1453-1459.e4. doi: 10.1016/j.cgh.2013.04.019. Epub 2013 Apr 30.Linked from NCT01394055
Related pages
Keep researching Relamorelin.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.